CELLSIGHT TECHNOLOGIES

effective and a few may develop adverse reaction to the immunotherapy. CellSight's PET tracer can help determine if a patient is immune ready or needs immune priming prior to the start of immunotherapy. Additionally, an on-treatment scan can help assess immunotherapy response early in the treatment cycle... Cancer immunotherapies that harness the body's immune system to help fight cancer do not work for everyone; in fact, success rates can be as low as 20%! Many patients seem to get worse before symptoms ease and clinical benefit can be observed. Some patients may discontinue treatment too early, some continue treatment even though it may not be... CellSight Technologies (CST), Inc. offers molecular imaging products and services to monitor survival, status, quantity and trafficking of therapeutic cells as well as the location and magnitude of therapeutic gene expression to predict efficacy and potential adverse effects in cell and gene therapy

Also known as: CellSight Technologies (CST), Inc., CellSight Technologies, Inc.

Primary location: San Francisco United States